Home Ingredients D-Chiro-Inositol
Women's HealthMetabolic HealthFertility

D-Chiro-Inositol

Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

D-chiro-inositol (DCI) is one of nine inositol stereoisomers and the rarer counterpart to myo-inositol (MI), which dominates in most tissues. The body converts MI to DCI tissue-specifically via insulin-stimulated epimerase activity, and DCI participates in inositol-phosphoglycan (IPG) second messengers downstream of insulin. The foundational 1999 trial by Nestler et al. in the New England Journal of Medicine established DCI as a candidate insulin-sensitizer for polycystic ovary syndrome (PCOS). Subsequent work has refined the model — high-dose DCI alone may paradoxically worsen ovarian function, leading to the Carlomagno-developed 40:1 myo-inositol:D-chiro-inositol combination protocol that is now the most-studied formulation.

Studied Dose DCI alone: 600-1,200 mg/day (older trials). Modern 40:1 MI:DCI: 4 g myo-inositol + 100 mg D-chiro-inositol per day, divided.
Active Compound D-chiro-inositol (a stereoisomer of inositol); often paired with myo-inositol in 40:1 ratio formulations.

Benefits

Supports Ovulation in PCOS

D-chiro-inositol supplementation has been studied for restoration of ovulation in women with PCOS, with the foundational NEJM trial showing 86% ovulation rate on DCI vs 27% on placebo over 6-8 weeks in obese women.

Supported by Trial 1, Trial 2

Supports Insulin Sensitivity

DCI participates in inositol-phosphoglycan second messengers downstream of insulin and was developed as a candidate insulin-sensitizer for women with PCOS-associated insulin resistance.

Supported by Trial 1, Trial 2

Modulates Androgens in PCOS

DCI treatment reduces circulating free testosterone and improves serum androgen profiles in women with PCOS, with effects observed in both obese and lean populations in early clinical work.

Supported by Trial 2, Trial 1

Optimal in 40:1 Ratio with Myo-Inositol

Modern protocols combine myo-inositol and D-chiro-inositol in a 40:1 ratio, mirroring the physiological plasma ratio in reproductively healthy women. High-dose DCI alone may paradoxically reduce oocyte quality.

Supported by Trial 3, Trial 2

May Support Metabolic Markers

DCI treatment has been associated with reductions in blood pressure, triglycerides, and serum insulin in lean and obese women with PCOS, suggesting broader metabolic effects beyond reproductive endpoints.

Supported by Trial 2, Trial 1

Mechanism of action

1

Inositol-Phosphoglycan (IPG) Second Messengers

DCI is incorporated into inositol-phosphoglycans that act as second messengers downstream of insulin receptor activation, supporting glucose disposal and insulin-mediated signaling.

2

Tissue-Specific MI-to-DCI Conversion

Insulin stimulates epimerase activity that converts myo-inositol to D-chiro-inositol in a tissue-specific manner. In PCOS ovaries, conversion may be elevated, leading to relative MI deficiency — the rationale for the 40:1 combination protocol.

3

Aromatase Modulation

At high doses, DCI may inhibit aromatase (estrogen-synthesizing enzyme), an effect that contributes to its androgen-lowering action but can also worsen ovarian function if MI is depleted.

4

Androgen Pathway Modulation

DCI supplementation lowers circulating free testosterone in PCOS, likely through combined effects on insulin signaling, aromatase activity, and downstream ovarian steroidogenesis.

Clinical trials

1
D-Chiro-Inositol for Ovulation in Obese PCOS — Foundational Trial

Randomized, double-blind, placebo-controlled trial of D-chiro-inositol (1,200 mg/day) vs placebo for 6-8 weeks in obese women with PCOS. Outcomes: ovulation rate (serum progesterone), serum androgens, oral glucose tolerance.

44 obese women with PCOS; 6-8 week intervention.

Ovulation occurred in 86% of women on DCI vs 27% on placebo. DCI also reduced serum free testosterone, blood pressure, and triglycerides while improving glucose-tolerance parameters. Established DCI as a candidate insulin-sensitizer in PCOS.

2
D-Chiro-Inositol in Lean Women with PCOS

Randomized, placebo-controlled trial of D-chiro-inositol (600 mg/day) vs placebo for 6-8 weeks in lean women with PCOS. Outcomes: serum insulin, androgens, ovulation, blood pressure, triglycerides.

20 lean women (BMI 20-24.4 kg/m²) with PCOS.

DCI reduced plasma insulin and free testosterone, lowered systolic and diastolic blood pressure and triglycerides, and induced ovulation in 60% vs 20% in placebo. Extended the PCOS finding from obese to lean phenotypes.

3
40:1 Myo-Inositol/D-Chiro-Inositol Ratio for PCOS — Ratio Comparison

Trial comparing seven different MI:DCI ratios (including DCI alone and 1:3.5, 2.5:1, 5:1, 20:1, 40:1, 80:1) in PCOS patients receiving 2 g of inositols twice daily for 3 months. Outcomes: ovulation, FSH, LH, SHBG, testosterone, HOMA index.

56 PCOS patients (8 per group); 3-month intervention.

The 40:1 MI:DCI ratio was the most effective at restoring ovulation and normalizing reproductive and metabolic parameters. DCI alone and ratios biased heavily toward DCI showed less favorable outcomes, supporting the modern 40:1 protocol.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated at typical doses in 40:1 combinations.
Mild nausea, gas, or diarrhea at higher DCI doses.
High DCI doses alone (>1,200 mg/day) may impair oocyte quality — prefer 40:1 protocol.
Headache or dizziness reported occasionally.
Limited safety data in pregnancy beyond first-trimester PCOS continuation studies.

Important Drug interactions

Antidiabetic medications (metformin, insulin) — additive blood-sugar effects; monitor when combining.
Hormonal contraceptives — inositol therapy is often used to improve ovulation; effects on contraceptive reliability not well studied.
Letrozole and clomiphene — sometimes used together for fertility; data on combined use is emerging but generally favorable.
Lithium — theoretical inositol depletion antagonism; clinical relevance unclear.

More Women's Health Ingredients

Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Cognitive
Vitamin B6 (Pyridoxine)
Vitamin B6 (pyridoxine) is a water-soluble vitamin essential for amino acid metabolism, ne…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol that acts as a secondary messenger in insu…
Mood & Mental Health
Saffron Extract (Crocus sativus)
Saffron is the dried stigmas of Crocus sativus — the most expensive spice in the world by…

Explore Other Ingredients

Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Metabolic Health
Fenugreek
Fenugreek is an annual plant native to the Mediterranean and South Asia, used for millenni…
Cognitive
KSM-66®
KSM-66 Ashwagandha, a standardized root extract, promotes stress relief and cognitive clar…

Frequently asked questions about D-Chiro-Inositol

What is the recommended dosage of D-Chiro-Inositol?

The clinically studied dose for D-Chiro-Inositol is DCI alone: 600-1,200 mg/day (older trials). Modern 40:1 MI:DCI: 4 g myo-inositol + 100 mg D-chiro-inositol per day, divided.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is D-Chiro-Inositol used for?

D-Chiro-Inositol is studied for supports ovulation in pcos, supports insulin sensitivity, modulates androgens in pcos. D-chiro-inositol supplementation has been studied for restoration of ovulation in women with PCOS, with the foundational NEJM trial showing 86% ovulation rate on DCI vs 27% on placebo over 6-8 weeks in obese women.

Are there side effects from taking D-Chiro-Inositol?

Reported potential side effects may include: Generally well-tolerated at typical doses in 40:1 combinations. Mild nausea, gas, or diarrhea at higher DCI doses. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does D-Chiro-Inositol interact with medications?

Known drug interactions may include: Antidiabetic medications (metformin, insulin) — additive blood-sugar effects; monitor when combining. Hormonal contraceptives — inositol therapy is often used to improve ovulation; effects on contraceptive reliability not well studied. Consult a pharmacist or healthcare provider if you take prescription medications.

Is D-Chiro-Inositol good for women's health?

Yes, D-Chiro-Inositol is researched for Women's Health support. D-chiro-inositol supplementation has been studied for restoration of ovulation in women with PCOS, with the foundational NEJM trial showing 86% ovulation rate on DCI vs 27% on placebo over 6-8 weeks in obese women.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314-20. doi: 10.1056/NEJM199904293401703.PubMedUsed to support: Foundational NEJM trial — 44 obese PCOS women; DCI 1,200 mg/day for 6-8 weeks induced ovulation in 86% vs 27% on placebo, with reductions in serum testosterone, blood pressure, and triglycerides.
  2. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8(6):417-23. doi: 10.4158/EP.8.6.417.PubMedUsed to support: 20 lean PCOS women; DCI 600 mg/day for 6-8 weeks reduced plasma insulin and free testosterone, lowered blood pressure and triglycerides, and induced ovulation in 60% vs 20% on placebo.
  3. Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512-5521. doi: 10.26355/eurrev_201906_18223.PubMedUsed to support: 56 PCOS patients across seven MI:DCI ratios; the 40:1 ratio was most effective at restoring ovulation and normalizing reproductive/metabolic parameters over 3 months, supporting the modern combination protocol.
  4. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95(8):2515-6. doi: 10.1016/j.fertnstert.2011.05.027.PubMedUsed to support: Commentary describing the 'D-chiro-inositol paradox' — high DCI doses can paradoxically worsen oocyte quality despite improving systemic insulin sensitivity, providing the rationale for the 40:1 MI:DCI ratio protocol.